Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06689228

The Effect of Education Based on Orem's Self-Care Deficit Theory and Tele-Monitoring on Rational Drug Use in Haemodialysis Patients

Patients with chronic kidney disease may show altered pharmacokinetic and pharmacodynamic response to many drugs compared to patients with normal renal function. Therefore, effective and safe drug use is difficult in patients with chronic kidney disease and especially in dialysis patients. In addition, some drugs may have nephrotoxic effects by causing further deterioration in renal function, especially in high-risk renal patients. Prevention of problems related to drug use in haemodialysis patients will be possible with rational drug use (RUD). RDM is defined as 'the set of rules to be followed in order for patients to take medicines in accordance with their clinical needs, in doses that meet their personal needs, in sufficient time, at the lowest cost to themselves and the society'.

Rational drug use has become an increasingly important concept today. In studies investigating rational drug use, problems such as incorrect use of drugs, prescribing more drugs than necessary, unnecessary injection recommendation/administration, unnecessary antibiotic consumption, and unnecessary use of expensive drugs have been identified. As a result of incorrect drug use, poisoning or decreased sensitivity to drugs are observed.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Burdur Mehmet Akif Ersoy University

Burdur, Bucak, 15300, Turkey (Türkiye)

About this study

The Effect of Education Based on Orem's Self-Care Deficit Theory and Tele-Monitoring on Rational Drug Use in Haemodialysis Patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older,
  • No communication or medically recognised mental problems,
  • Patients receiving haemodialysis treatment for 6 months or longer were included in the study.

Exclusion criteria

  • Diagnosed with psychiatric illness
  • Diagnosed with malignancy
  • Individuals who do not allow access to their information.

Treatment and study plan

Rational Drug Use Training

Other

Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.

Other names: Tele-monitoring

Primary outcomes

  1. Rationanl Drug use Scale

    Time frame: two months

    The Rational Drug Use Scale (RUDS) consists of 21 items and one dimension (Appendix 3). The items are scored on a 5-point Likert-type scale (1-Never, 2-Rarely, 3-Sometimes, 4-Most of the time and 5-Always) according to their fulfilment of the statements. Only the 17th item in the scale is reversed. After the reversed item is reversed, the sum of all scale items gives the 'total scale score'. The total score of the EHRS varies between 21 and 105. As the total score obtained from AİKÖ increases, rational drug use increases. When evaluating the total score obtained from AİKÖ; if the total score obtained is between 21- 52, it is scored as low level, between 53-67 as medium level, and between 68-105 as high level.

Sponsors and collaborators

Lead sponsor

Akdeniz University

Other

Registry information

Official study title

Principal Investigator

Acronym: Haemodialysis

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Nov 14, 2024
Registry last updated
Nov 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.